Stimulants and growth in children with attention-deficit/hyperactivity disorder

Medical Hypotheses

Volumn 77, Issue 1, 2011, Pages 21-28

  Negrao, Bianca Lee ^a   Viljoen, Margaretha ^b  

^a UNIVERSITY OF JOHANNESBURG   (South Africa)

^b University of Pretoria   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CENTRAL STIMULANT AGENT; DOPAMINE; GROWTH HORMONE; INSULIN; NORADRENALIN; PROLACTIN; SEX HORMONE; TESTOSTERONE; THYROID HORMONE;

ARTICLE; ATTENTION DEFICIT DISORDER; CELL METABOLISM; CHILD GROWTH; GROWTH INHIBITION; HOMEOSTASIS; HORMONE RELEASE; HUMAN; NONHUMAN; PROTEIN SYNTHESIS; SYNAPSE;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; GONADAL STEROID HORMONES; GROWTH; HUMANS; INSULIN; THYROID HORMONES;

EID: 79958075709     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.03.015     Document Type: Article

References (124)

1. Roche A.F., Lipman R.S., Overall J.E., Hung W. The effects of stimulant medication on the growth of hyperkinetic children. Pediatrics 1979, 63(6):847-850.
2. Bereket A., Turan S., Karaman M.G., Haklar G., Ozbay F., Yazgan M.Y. Height, weight, IGF-1, IGFBP-3 and thyroid functions in prepubertal children with attention deficit hyperactivity disorder: effect of methylphenidate treatment. Horm Res 2005, 63:159-164.
3. Spencer T.J., Faraone S.V., Biederman J., et al. Does prolonged therapy with a long-acting stimulant suppress growth in children with ADHD?. J Am Acad Child Adolesc Psychiatry 2006, 45(5):527-537.
4. Zachor D.A., Roberts A.W., Hodgens J.B., Isaacs J.S., Merrick J. Effects of long-term psychostimulant medication on growth of children with ADHD. Res Dev Disabil 2006, 27:162-174.
5. Faraone S.V., Biederman J., Morley C.P., Spencer T.J. Effect of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry 2008, 47(9):994-1009.
6. Swanson J.M., Elliott G.R., Greenhill L.L., et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry 2007, 46(8):1015-1027.
7. Swanson J., Greenhill L., Wigal T., et al. Stimulant-related reductions of growth rates in the PATS. J Am Acad Child Adolesc Psychiatry 2006, 45(11):1304-1313.
8. Poulton A., Cowell C.T. Slowing of growth in height and weight on stimulants: a characteristic pattern. J Paediatr Child Health 2003, 39:180-185.
9. MTA Cooperative Group National Institute of Mental Health multimodal treatment study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics 2004, 113(4):762-769.
10. Sund A.M., Zeiner P. Does extended medication with amphetamine or methylphenidate reduce growth in hyperactive children?. Nord J Psychiatry 2002, 56(1):53-57.
11. Spencer T.J., Biederman J., Harding M., O' Donnell D., Faraone S.V., Wilens T.E. Growth deficits in ADHD children revisited: evidence for disorder-associated growth delays?. J Am Acad Child Adolesc Psychiatry 1996, 35(11):1460-1469.
12. Gross M.D. Growth of hyperkinetic children taking methylphenidate, dextroamphetamine, or imipramine/desipramine. Pediatrics 1976, 58(3):423-431.
13. Millichap J.G. Growth of hyperactive children treated with methylphenidate. J Learn Disabil 1978, 11(9):567-570.
14. Satterfield J.H., Cantwell D.P., Schell A., Blaschke T. Growth of hyperactive children treated with methylphenidate. Arch Gen Psychiatry 1979, 36(2):212-217.
15. Loney J., Whaley-Klahn M.A., Ponto L.B., Adney K. Predictors of adolescent height and weight in hyperkinetic boys treated with methylphenidate [proceedings]. Psychopharmacol Bull 1981, 17(1):132-134.
16. Mattes J.A., Gittelman R. Growth of hyperactive children on maintenance regimen of methylphenidate. Arch Gen Psychiatry 1983, 40(3):317-321.
17. Safer D., Allen R., Barr E. Depression of growth in hyperactive children on stimulant drugs. N Engl J Med 1972, 287:217-220.
18. Greenhill L.L., Puig-Antich J., Novacenko H., et al. Prolactin, growth hormone and growth responses in boys with attention deficit disorder and hyperactivity treated with methylphenidate. J Am Acad Child Psychiatry 1984, 23(1):58-67.
19. Safer D.J., Allen R.P. Factors influencing the suppressant effects of two stimulant drugs on the growth of hyperactive children. Pediatrics 1973, 51(4):660-667.
20. Zhang H.Y., Du M.L., Zhuang S.Q., Liu M.N. Influence of methylphenidate on growth of school age children with attention deficit hyperactivity disorder. Zhonghua Er Ke Za Zhi 2005, 43(10):723-727.
21. Faraone S.V., Giefer E.E. Long-term effects of methylphenidate transdermal delivery system treatment of ADHD on growth. J Am Acad Child Adolesc Psychiatry 2007, 46(9):1138-1147.
22. Poulton A. Growth on stimulant medication; clarifying the confusion: a review. Arch Dis Child 2005, 90:801-806.
23. Lisska M.C., Rivkees S.A. Daily methylphenidate use slows the growth of children: a community based study. J Pediatr Endocrinol Metab 2003, 16(5):711-718.
24. Faraone S.V., Spencer T.J., Kollins S.H., Glatt S.J. Effects of lisdexamfetamine dimesylate treatment for ADHD on growth. J Am Acad Child Adolesc Psychiatry 2010, 49(1):24-32.
25. Pliszka S.R., Matthews T.L., Braslow K.J., Watson M.A. Comparative effects of methylphenidate and mixed salts amphetamine on height and weight in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006, 45(5):520-526.
26. Montgomery A.J., Asselin M., Farde L., Grasby P.M. Measurement of methylphenidate-induced change in extrastriatal dopamine concentration using [11C]FLB 457 PET. J Cereb Blood Flow Metab 2007, 27:369-377.
27. Arnsten A.F.T., Dudley A.G. Methylphenidate improves prefrontal cortical cognitive function through α2 adrenoceptor and dopamine D1 receptor actions: relevance to therapeutic effects in attention deficit hyperactivity disorder. Behav Brain Funct 2005, 1(1):2.
28. Carboni E., Silvagni A. Experimental investigations on dopamine transmission can provide clues on the mechanism of the therapeutic effect of amphetamine and methylphenidate in ADHD. Neural Plast 2004, 11(1-2):77-95.
29. Vles J.S., Feron F.J., Hendriksen J.G., Jolles J., van Kroonenburgh M.J., Weber W.E. Methylphenidate down-regulates the dopamine receptor and transporter system in children with attention deficit hyperkinetic disorder (ADHD). Neuropediatrics 2003, 34(2):77-80.
30. Volz T.J., Farnsworth S.J., Rowley S.D., Hanson G.R., Fleckenstein A.E. Methylphenidate-induced increases in vesicular dopamine sequestration and dopamine release in the striatum: the role of muscarinic and dopamine D2 receptors. J Pharmacol Exp Ther 2008, 327(1):161-167.
31. Russell V., de Villiers A., Sagvolden T., Lamm M., Taljaard J. Differences between electrically-, ritalin- and D-amphetamine-stimulated release of [3H]dopamine from brain slices suggest impaired vesicular storage of dopamine in an animal model of attention-deficit hyperactivity disorder. Behav Brain Res 1998, 94(1):163-171.
32. Sandoval V., Riddle E.L., Hanson G.R., Fleckenstein A.E. Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptors. J Neurosci 2002, 22(19):8705-8710.
33. Volkow N.D., Wang G.J., Fowler J.S., et al. "Nonhedonic" food motivation in humans involves dopamine in the dorsal striatum and methylphenidate amplifies this effect. Synapse 2002, 44(3):175-180.
34. Tilley M.R., Gu H.H. The effects of methylphenidate on knockin mice with a methylphenidate-resistant dopamine transporter. J Pharmacol Exp Ther 2008, 327(2):554-560.
35. Kuczenski R., Segal D.S. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem 1997, 68(5):2032-2037.
36. Haag M., Kruger M.C. Human physiology 2004, 18.1-18.67. Juta, Pretoria. 3rd ed. B.J. Meyer, D.H. Van Papendorp, H.S. Meij, M. Viljoen (Eds.).
37. Holtkamp K., Peters-Wallraf B., Wüller S., Pfäaffle R., Herpertz-Dahlmann B. Methylphenidate-related growth impairment. J Child Adolesc Psychopharmacol 2002, 12(1):55-61.
38. Barter M., Krammer H. Methylphenidate and growth retardation. JAMA 1978, 239(17):1742-1743.
39. Aarskog D., Fevang F.O., Klove H., Stoa K.F., Thorsen T. The effect of the stimulant drugs, dextroamphetamine and methylphenidate, on secretion of growth hormone in hyperactive children. J Pediatr 1977, 90(1):136-139.
40. Hunt R.D., Cohen D.J., Anderson G., Clark L. Possible change in noradrenergic receptor sensitivity following methylphenidate treatment: growth hormone and MHPG response to clonidine challenge in children with attention deficit disorder and hyperactivity. Life Sci 1984, 35(8):885-897.
41. Kilgore B.S., Dickinson M.A., Burnett C.R., Lee J., Schedewie H.K., Elders M.J. Alterations in cartilage metabolism by neurostimulant drugs. J Pediatr 1979, 94(4):542-545.
42. Brown W.A., Williams B.W. Methylphenidate increases serum growth hormone concentrations. J Clin Endocrinol Metab 1976, 43(4):937-939.
43. Joyce P.R., Donald R.A., Nicholls M.G., Livesey J.H., Abbott R.M. Endocrine and behavioural responses to methylphenidate in normal subjects. Biol Psychiatry 1986, 21(11):1015-1023.
44. Shaywitz S.E., Hunt R.D., Jatlow P., et al. Psychopharmacology of attention deficit disorder: pharmacokinetic, neuroendocrine, and behavioral measures following acute and chronic treatment with methylphenidate. Pediatrics 1982, 69(6):688-694.
45. Toren P., Silbergeld A., Eldar S., et al. Lack of effect of methylphenidate on serum growth hormone (GH), GH-binding protein, and insulin-like growth factor I. Clin Neuropharmacol 1997, 20(3):264-269.
46. Van den Berghe G., de Zegher F., Lauwers P., Veldhuis J.D. Growth hormone secretion in critical illness: effect of dopamine. J Clin Endocrinol Metab 1994, 79(4):1141-1146.
47. Svoboda T., Kotzmann H., Clodi M., Bernecker P., Geyer G., Luger A. The non ergot D2-dopamine agonist CV 205-502 decreases growth hormone concentrations in acromegalic patients. Endocr Res 1994, 20(1):59-63.
48. De Zegher F., Van den Berghe G., Devlieger H., Eggermont E., Veldhuis J.D. Dopamine inhibits growth hormone and prolactin secretion in the human newborn. Pediatr Res 1993, 34(5):642-645.
49. Miell J.P., Pralong F.P., Corder R., Gaillard R.C. Stimulation of growth hormone release in man by the potent D2-dopamine agonist CV 205-502: comparison of responses to intravenous and oral administration. J Clin Endocrinol Metab 1990, 71(6):1519-1524.
50. Boesgaard S., Hagen C., Andersen A.N., Eldrup E., Lange P. Effect of fenoldopam, a dopamine D-1 receptor agonist, on pituitary, gonadal and thyroid hormone secretion. Clin Endocrinol (Oxf) 1989, 30(3):231-239.
51. Ferrari C., Rampini P., Paracchi A., Boghen M., Mailland F. Effect of dihydroergokryptine administration on serum prolactin and growth hormone levels in normal, hyperprolactinaemic and acromegalic subjects: evidence of potent and long-lasting pituitary dopamine receptor stimulation. Eur J Clin Pharmacol 1985, 27(6):707-711.
52. Camanni F., Massara F., Belforte L., Rosatello A., Molinatti G.M. Effect of dopamine on plasma growth hormone and prolactin levels in normal and acromegalic subjects. J Clin Endocrinol Metab 1977, 44(3):465-473.
53. Durá Travé T., Juste Ruiz M., González Montero R., Gutiérrez Terán M., Mauri Dot M., Moya Benavent M. Sensitivity of the clonidine and guanfacine tests (alpha-2-adrenergic agonists) as pharmacologic stimulants of growth hormone. Effects on plasma cortisol. An Esp Pediatr 1996, 45(6):575-578.
54. Hoehe M., Valido G., Matussek N. Growth hormone, noradrenaline, blood pressure and cortisol responses to clonidine in healthy male volunteers: dose-response relations and reproducibility. Psychoneuroendocrinology 1988, 13(5):409-418.
55. Struthers A.D., Burrin J.M., Brown M.J. Exercise-induced increases in plasma catecholamines and growth hormone are augmented by selective alpha 2-adrenoceptor blockade in man. Neuroendocrinology 1986, 44(1):22-28.
56. Lechin F., van der Dijs B., Jakubowicz D., et al. Effects of clonidine on blood pressure, noradrenaline, cortisol, growth hormone, and prolactin plasma levels in high and low intestinal tone depressed patients. Neuroendocrinology 1985, 41(2):156-162.
57. Law G.J., Ray K.P., Wallis M. Effects of growth hormone-releasing factor, somatostatin and dopamine on growth hormone and prolactin secretion from cultured ovine pituitary cells. FEBS Lett 1984, 166(1):189-193.
58. McMahon C.D., Chapin L.T., Lookingland K.J., Tucker H.A. Stimulation of dopamine D1 receptors increases activity of periventricular somatostatin neurons and suppresses concentrations of growth hormone. Domest Anim Endocrinol 1998, 15(4):257-265.
59. Kentroti S., McCann S.M. Role of dopamine in the inhibitory control of growth hormone and prolactin release by gastrin-releasing peptide. Brain Res Bull 1996, 39(4):201-204.
60. Ishibashi M., Yamaji T. Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture. J Clin Invest 1984, 73(1):66-78.
61. Lee E.K.Y., Chan V.C.C., Chang J.P., Yunker W.K., Wong A.O.L. Norepinephrine regulation of growth hormone release from goldfish pituitary cells. I. Involvement of α2 adrenoreceptor and interactions with dopamine and salmon gonadotropin-releasing hormone. J Neuroendocrinol 2000, 12:311-322.
62. Safer D.J., Allen R.P., Barr E. Growth rebound after termination of stimulant drugs. J Pediatr 1975, 86(1):113-116.
63. Muller E.E., Locatelli V., Ghigo E., et al. Involvement of brain catecholamines and acetylcholine in growth hormone deficiency states. Pathophysiological, diagnostic and therapeutic implications. Drugs 1991, 41(2):161-177.
64. Keeler C., Jablonski E.M., Albert Y.B., et al. The kinetics of binding human prolactin, but not growth hormone, to the prolactin receptor vary over a physiologic pH range. Biochemistry 2007, 46(9):2398-2410.
65. Genuth S.M. Physiology 1998, 779-1011. Mosby, St. Louis. 4th ed. R.M. Berne, M.N. Levy (Eds.).
66. Mick C.C., Nicoll C.S. Prolactin directly stimulates the liver in vivo to secrete a factor (synlactin) which acts synergistically with the hormone. Endocrinology 1985, 116(5):2049-2053.
67. Delidow B.C., Baldocchi R.A., Nicoll C.S. Evidence for hepatic involvement in the regulation of amphibian development by prolactin. Gen Comp Endocrinol 1988, 70(3):418-424.
68. McNeilly A.S., Friesen H.G. Presence of a nonlactogenic factor in human serum which synergistically enhances prolactin-stimulated growth of Nb2 rat lymphoma cells in vitro. J Clin Endocrinol Metab 1985, 61(3):408-411.
69. Puig-Antich J., Greenhill L.L., Sassin J., Sachar E.J. Growth hormone, prolactin and cortisol responses and growth patterns in hyperkinetic children treated with dextro-amphetamine: preliminary findings. J Am Acad Child Psychiatry 1978, 17(3):457-475.
70. Martin W.H., Rogol A.D., Kaiser D.L., Thorner M.O. Dopaminergic mechanisms and luteinizing hormone (LH) secretion. II. Differential effects of dopamine and bromocriptine on LH release in normal women. J Clin Endocrinol Metab 1981, 52(4):650-656.
71. Martin M.C., Monroe S.E., Weiner R.I., Jaffe R.B. Low-dose dopamine infusions do not ablate luteinizing hormone pulses in women. Am J Obstet Gynecol 1988, 159(4):898-903.
72. Harrison R.F., Synnott M., O' Moore R., O' Moore M. Can women with gonadotropin levels diagnostic of polycystic ovarian syndrome benefit from therapy with dopamine agonists?. Ann NY Acad Sci 1993, 687:272-279.
73. Paradisi R., Margrini O., Venturoli S., et al. Naloxone does not interfere with the dopamine-induced decrease in gonadotropin secretion in women with polycytic ovarian disease. Horm Metab Res 1985, 17(1):29-31.
74. Judd S.J., Rakoff J.S., Yen S.S. Inhibition of gonadotropin and prolactin release by dopamine: effect of endogenous estradiol levels. J Clin Endocrinol Metab 1978, 47(3):494-498.
75. Kontogeorgos G., Horvath E., Kovacs K., et al. Morphologic changes of prolactin-producing pituitary adenomas after short treatment with dopamine agonists. Acta Neuropathol 2006, 111(1):46-52.
76. Schilling T., Gründling M., Strang C.M., Möritz K.U., Siegmund W., Hachenberg T. Effects of dopexamine, dobutamine or dopamine on prolactin and thyreotropin serum concentrations in high-risk surgical patients. Intensive Care Med 2004, 30(6):1127-1133.
77. Bailey A.R., Burchett K.R. Effect of low-dose dopamine on serum concentrations of prolactin in critically ill patients. Br J Anaesth 1997, 78(1):97-99.
78. Schlegel S., Schlösser R., Hiemke C., Nickel O., Bockisch A., Hahn K. Prolactin plasma levels and D2-dopamine receptor occupancy measured with IBZM-SPECT. Psychopharmacology (Berl) 1996, 124(3):285-287.
79. Rotrosen J., Angrist B., Clark C., Gershon S., Halpers F.S., Sachar E.J. Suppression of prolactin by dopamine agonists in schizophrenics and controls. Am J Psychiatry 1978, 135(8):949-951.
80. Serri O., Kuchel O., Buu N.T., Somma M. Differential effects of a low dose dopamine infusion on prolactin secretion in normal and hyperprolactinemic subjects. J Clin Endocrinol Metab 1983, 56(2):255-259.
81. Melis G.B., Paoletti A.M., Mais V., Fioretti P. Interference of dopamine infusion on gamma-amino butyric acid (GABA)-stimulated prolactin increase. J Endocrinol Invest 1980, 3(4):445-448.
82. Massara F., Camanni F., Vergano V., Belforte L., Molinatti G.M. Inhibition of thyrotropin and prolactin secretion by dopamine in man. J Endocrinol Invest 1978, 1(1):25-30.
83. McPherson H., Walsh A., Silverstone T. Growth hormone and prolactin response to apomorphine in bipolar and unipolar depression. J Affect Disord 2003, 76(1-3):121-125.
84. Van den Berghe G., de Zegher F., Vlasselaers D., et al. Thyrotropin-releasing hormone in critical illness: from a dopamine-dependent test to a strategy for increasing low serum triiodothyronine, prolactin, and growth hormone concentrations. Crit Care Med 1996, 24(4):590-595.
85. Besses G.S., Burrow G.N., Spaulding S.W., Donabedian R.K. Dopamine infusion acutely inhibits the TSH and prolactin response to TRH. J Clin Endocrinol Metab 1975, 41(5):985-988.
86. Connell J.M., Ball S.G., Balmforth A.J., Beastall G.H., Davies D.L. Effect of low-dose dopamine infusion on basal and stimulated TSH and prolactin concentrations in man. Clin Endocrinol (Oxf) 1985, 23(2):185-192.
87. Fitzgerald P., Dinan T.G. Prolactin and dopamine: what is the connection? A review article. J Psychopharmacol 2008, 22(Suppl 2):12-19.
88. Boesgaard S., Hagen C., Hangaard J., Andersen A.N., Eldrup E. Pulsatile gonadotropin secretion and basal prolactin levels during dopamine D-1 receptor stimulation in normal women. Fertil Steril 1991, 55(2):281-286.
89. Fabbrini G., Braun A., Mouradian M.M., Tamminga C.A., Chase T.N. Dopamine D-1 receptor agonist stimulation of prolactin secretion in man. J Neural Transm 1988, 71(3):159-163.
90. Colthorpe K.L., Nalliah J., Anderson S.T., Curlewis J.D. Adrenoceptor subtype involvement in suppression of prolactin secretion by noradrenaline. J Neuroendocrinol 2000, 12(4):297-302.
91. Budziszewska B., Jaworska-Feil L., Lasoń W. The effect of repeated amphetamine and cocaine administration on adrenal, gonadal and thyroid hormone levels in the rat plasma. Exp Clin Endocrinol Diabetes 1996, 104(4):334-338.
92. de Zegher F., Van den Berghe G., Dumoulin M., Gewillig M., Daenen W., Devlieger H. Dopamine suppresses thyroid-stimulating hormone secretion in neonatal hypothyroidism. Acta Paediatr 1995, 84(2):213-214.
93. Kaptein E.M., Spencer C.A., Kamiel M.B., Nicoloff J.T. Prolonged dopamine administration and thyroid hormone economy in normal and critically ill subjects. J Clin Endocrinol Metab 1980, 51(2):387-393.
94. Köbberling J., Darragh A., Del Pozo E. Chronic dopamine receptor stimulation using bromocriptine: failure to modify thyroid function. Clin Endocrinol (Oxf) 1979, 11(4):367-370.
95. Meyer B.J., Van Papendorp D.H., Meij H.S., Viljoen M. Human physiology 2004, 19.1-19.25. Juta, Pretoria. 3rd ed. B.J. Meyer, D.H. Van Papendorp, H.S. Meij, M. Viljoen (Eds.).
96. Veldhuis J.D., Hudson S.B., Erickson D., Bailey J.N., Reynolds G.A., Bowers C.Y. Relative effects of estrogen, age, and visceral fat on pulsatile growth hormone secretion in healthy women. Am J Physiol Endocrinol Metab 2009, 60(2):E367-E374.
97. Bondanelli M., Ambrosio M.R., Margutti A., Franceschetti P., Zatelli M.C., Degli Uberti E.C. Activation of the somatotropic axis by testosterone in adult men: evidence for a role of hypothalamic growth hormone-releasing hormone. Neuroendocrinology 2003, 77(6):380-387.
98. Muniyappa R., Sorkin J.D., Veldhuis J.D., et al. Long-term testosterone supplementation augments overnight growth hormone secretion in healthy older men. Am J Physiol Endocrinol Metab 2007, 56(3):E769-E775.
99. Hibel L.C., Granger D.A., Cicchetti D., Rogosch F. Salivary biomarker levels and diurnal variation: associations with medications prescribed to control children's problem behavior. Child Dev 2007, 78(3):927-937.
100. Adriani W., Leo D., Guarino M., et al. Short-term effects of adolescent methylphenidate exposure on brain striatal gene expression and sexual/endocrine parameters in male rats. Ann NY Acad Sci 2006, 1074(1):52-73.
101. Kaneyuki T., Kohsaka M., Shohmori T. Sex hormones metabolism in the brain: influence of central acting drugs on 5 alpha-reduction in rat diencephalon. Endocrinol Jpn 1979, 26(3):345-351.
102. Tsai S.C., Chiao Y.C., Lu C.C., et al. Inhibition by amphetamine of testosterone secretion through a mechanism involving an increase of cyclic AMP production in rat testes. Br J Pharmacol 1996, 118(4):984-988.
103. Chatterjee-Chakrabarty S., Miller B.T., Collins T.J., Nagamani M. Adverse effects of methylphenidate on the reproductive axis of adolescent female rats. Fertil Steril 2005, 84(Suppl 2):1131-1138.
104. Van den Berghe G., de Zegher F., Lauwers P., Veldhuis J.D. Luteinizing hormone secretion and hypoandrogenaemia in critically ill men: effect of dopamine. Clin Endocrinol (Oxf) 1994, 41(5):563-569.
105. Nicoletti I., Ambrosi F., Giammartino C., Fedeli L., Mannarelli C., Filipponi P. Catecholamines and pituitary-function. V. Effect of low-dose dopamine infusion on basal and gonadotropin-releasing hormone stimulated gonadotropin release in normal cycling women and patients with hyperprolactinemic amenorrhea. Horm Metab Res 1986, 18(7):479-484.
106. Barnes R.B., Cha K.Y., Lee D.G., Lobo R.A. Modulation of luteinizing hormone immunoreactivity and bioactivity by dopamine but not norepinephrine in women. Am J Obstet Gynecol 1986, 154(2):445-450.
107. Foresta C., Scanelli G., Marra S., Scandellari C. The influence of gonadal steroids on the dopamine inhibitory effect on gonadotropin release in men. Fertil Steril 1984, 42(6):942-945.
108. Ferrari C., Rampini P., Malinverni A., et al. Inhibition of luteinizing hormone release by dopamine infusion in healthy women and in various pathophysiological conditions. Acta Endocrinol (Copenh) 1981, 97(4):436-440.
109. Quigley M.E., Rakoff J.S., Yen S.S. Increased luteinizing hormone sensitivity to dopamine inhibition in polycystic ovary syndrome. J Clin Endocrinol Metab 1981, 52(2):231-234.
110. Judd S.J., Rigg L.A., Yen S.S. The effects of ovariectomy and estrogen treatment on the dopamine inhibition of gonadotropin and prolactin release. J Clin Endocrinol Metab 1979, 49(2):182-184.
111. Silverthorn D.U. Human physiology: an integrated approach 2004, 696-720. Benjamin Cummings, San Francisco. 3rd ed. D.U. Silverthorn (Ed.).
112. Martini F.H., Nath J.L. Fundamentals of anatomy and physiology 2009, 604-644. Benjamin Cummings, San Francisco. 8th ed. F.H. Martini, J.L. Nath (Eds.).
113. Guyton A.C., Hall J.E. Textbook of medical physiology 2006, 961-977. Elsevier Saunders, Philadelphia. 11th ed. A.C. Guyton, J.E. Hall (Eds.).
114. Bello N.T., Hajnal A. Acute methylphenidate treatments reduce sucrose intake in restricted-fed bingeing rats. Brain Res Bull 2006, 70(4-6):422-429.
115. McMahon E.M., Andersen D.K., Feldman J.M., Schanberg S.M. Methamphetamine-induced insulin release. Science 1971, 174(4):66-68.
116. Manzanares J., Cantón R., Grande C., Benedi J., Zaragozá F. Amphetamine and chlorpromazine modify cerebral insulin levels in rats. Life Sci 1988, 42(1):21-25.
117. Kuo D.Y., Cheng J.T. Role of cerebral dopamine but not plasma insulin, leptin and glucocorticoid in the development of tolerance to the anorectic effect of amphetamine. Neurosci Res 2002, 44(1):63-69.
118. van Weenen J.E., Parlevliet E.T., Maechler P., et al. The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the α2-adrenergic receptors in beta cells. Biochem Pharmacol 2010, 79(12):1827-1836.
119. Jones P.M., Asare-Anane H., Weerasinghe C., Persaud S.J. Dopamine is an intra-islet regulator of insulin secretion. Diabetes 2007, 56(Suppl. 1):A439.
120. Shankar E., Santhosh K.T., Paulose C.S. Dopaminergic regulation of glucose-induced insulin secretion through dopamine D2 receptors in the pancreatic islets in vitro. IUBMB Life 2006, 58(3):157-163.
121. Rubi B., Ljubicic S., Pournourmohammadi S., et al. Dopamine D2-like receptors are expressed in pancreatic beta cells and mediate inhibition of insulin secretion. J Biol Chem 2005, 280(44):36824-36832.
122. Walters J.M., Ward G.M., Barton J., et al. The effect of norepinephrine on insulin secretion and glucose effectiveness in non-insulin-dependent diabetes. Metabolism 1997, 46(12):1448-1453.
123. Porte D., Williams R.H. Inhibition of insulin release by norepinephrine in man. Science 1966, 152(3726):1248-1250.
124. Cheng H., Straub S.G., Sharp G.W.G. Protein acylation in the inhibition of insulin secretion by norepinephrine, somatostatin, galanin, and PGE[sub 2]. Am J Physiol Endocrinol Metab 2003, 48(2):E287-E294.